Online inquiry

IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11974MR)

This product GTTS-WQ11974MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB3&IGF1R gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005915.1; NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065; 3480
UniProt ID P21860; P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11974MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7392MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ11360MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ584MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ7398MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ1306MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ11998MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ10839MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ8995MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMA-638
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW